Help us improve this page by adding information.
Visit our Writing Guide or this topic page for additional help.
Visit our Writing Guide or this topic page for additional help.
Timeline
November 20, 2020
Glycostem Therapeutics announces the opening of a phase I/IIa trial for its lead product oNKord® for the treatment of AML patients.
2007
Glycostem was founded.
People
Name
Role
LinkedIn
Hareth Nahi
CMO
Jan Spanholtz
CSO
Troels Jordansen
CEO
Volker Huppert
COO
Further reading
Title
Author
Link
Type
Date
Documentaries, videos and podcasts
Title
Date
Link
Companies
Company
CEO
Location
Products/Services
News
Title
Author
Date
Publisher
Description
Glycostem Therapeutics
December 15, 2020
www.prnewswire.com:443
/PRNewswire/ -- Glycostem Therapeutics B.V., a leading clinical-stage company focused on the development of therapeutic off-the-shelf Natural Killer (NK)...
Glycostem Therapeutics
November 20, 2020
www.prnewswire.com:443
/PRNewswire/ -- Glycostem Therapeutics B.V., a leading clinical-stage company focused on the development of therapeutic off-the-shelf Natural Killer (NK)...
References
Is a
CompanyCompany attributes
Biotechnology
Biomedical engineering
Immunotherapy
Stem cellLocation
NetherlandsDate incorporated
2007
Founded date
2007
Other attributes
Country
